Endologix Appoints Matthew Thompson, M.D., as Chief Medical Officer
October 25 2016 - 09:00AM
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative
treatments for aortic disorders, announced the appointment of
Matthew Thompson, M.D., as Chief Medical Officer effective December
2016. He succeeds David Deaton, M.D., who will continue to work
with the Company as a consultant.
John McDermott, Chief Executive Officer of
Endologix, said, “We are excited to have Dr. Thompson join the
Endologix leadership team. He is an international thought leader in
vascular surgery and endovascular therapies, and shares our
dedication to patient care. His deep experience treating a wide
variety of aortic conditions will benefit our clinical programs,
physician training initiatives and product development. In
addition, Dr. Thompson is one of our most experienced Nellix® users
and clinical investigators, providing an excellent background
across EVAR and EVAS.”
Mr. McDermott added, "I want to thank Dr. Deaton
for his service as Chief Medical Officer and his significant
contributions to the Company over the past few years. We look
forward to continuing to work with Dr. Deaton in the future."
Dr. Thompson commented, “I look forward to this new
chapter in my career and am thrilled to be joining one of the most
innovative companies in endovascular aortic therapy. Endologix’s
passion and commitment to patient safety and outcomes makes the
position a natural fit that allows me to continue serving patients
with aortic disorders, but now on a global scale.”
Most recently, Dr. Thompson served as Professor of
Vascular Surgery at St. George’s, University of London and St
George’s Vascular Institute (SGVI). He trained at Cambridge, St.
Bartholomew’s Hospital, the University of Leicester and Adelaide.
His awards include a Hunterian Professorship, the Moynihan
travelling fellowship and the gold medal for the intercollegiate
examination. Dr. Thompson is also the editor of the Oxford Textbook
of Vascular Surgery and the Oxford Handbook of Vascular Surgery. He
was Chair of the National Specialized Commissioning Clinical
Reference Group for Vascular Services and is a founder of the
British Society for Endovascular Therapy. Dr. Thompson is also a
Council Member of the Vascular Society, Chairman of the Vascular
Society Annual Scientific Meeting and elected President for
2018.
About Endologix, Inc.Endologix,
Inc., develops and manufactures minimally invasive treatments for
aortic disorders. The Company's focus is endovascular stent grafts
for the treatment of abdominal aortic aneurysms (AAA). AAA is a
weakening of the wall of the aorta, the largest artery in the body,
resulting in a balloon-like enlargement. Once AAA develops, it
continues to enlarge and, if left untreated, becomes increasingly
susceptible to rupture. The overall patient mortality rate for
ruptured AAA is approximately 80%, making it a leading cause of
death in the United States. Additional information can be found on
Endologix's website at www.endologix.com.
COMPANY CONTACT:
Endologix, Inc.
John McDermott, CEO
Vaseem Mahboob, CFO
(949) 595-7200
www.endologix.com
INVESTOR CONTACTS:
The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Mar 2023 to Mar 2024